Drug Profile
LY 2881835
Alternative Names: LY2881835Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action FFAR1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 26 Aug 2011 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in Singapore (NCT01358981)
- 06 Jun 2011 Phase-I clinical trials in Type-2 diabetes mellitus in Singapore (PO)